Frankfurt/Munich, June 30, 2021 – McDermott Will & Emery advised Merck KGaA on a collaboration agreement with neuroloop GmbH, a B. Braun subsidiary and early-stage start-up company based in Freiburg, Germany.
The collaboration seeks to develop a neurostimulator device that may complement the existing drug therapies for patients with chronic inflammatory diseases. Initial data is expected by the end of 2022 and will subsequently be evaluated in a clinical trial. Once development is complete approval will be sought in major markets, such as the European Union and the United States.
neuroloop GmbH is a spin-off of the University of Freiburg and the Freiburg University Medical Center. Since its foundation in 2015, the company has been exclusively financed by Aesculap AG, the surgical division of the B. Braun Group.
Merck, a leading science and technology company with around 58,000 employees, is active in the fields of healthcare, life science and performance materials. In 2020, the Group generated sales of € 17.5 billion in 66 countries.
The joint development agreement with B. Braun and neuroloop represents a milestone in the new Bioelectronics innovation field of Merck.
Merck’s inhouse team comprised Dariush Bahreini, Willem F.C. de Weerd and Holger Pittroff.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.